Literature DB >> 26549745

Psychometric Properties of the Asthma Symptom Diary (ASD), a Diary for Use in Clinical Trials of Persistent Asthma.

Gary Globe1, Ingela Wiklund2, Joseph Lin3, Wen-Hung Chen4, Mona Martin5, Maria S Mattera4, Robyn von Maltzahn2, Jing Yuan Feng6, Yun Chon6, Hema N Viswanathan6, Michael Schatz7.   

Abstract

BACKGROUND: No currently available asthma symptom diary has sufficient validation to be recommended for use as a core asthma outcome measure.
OBJECTIVE: The objective of this study was to provide validation data for the 10-item asthma symptom diary (ASD).
METHODS: Data were collected in a 4-week prospective, observational study. Subjects completed 3 study visits, completing the ASD twice daily at home for 28 days. Psychometric properties in terms of dimensionality, reliability, validity, and responsiveness were assessed.
RESULTS: Data from 276 subjects were analyzed; mean age was 42.9 (standard deviation [SD] = 16.4) years, mean asthma duration was 23.3 (SD = 16.8) years, and 69.6% were female. Confirmatory factor and Rasch analysis supported the ASD as unidimensional and adequately measuring the spectrum of asthma symptom severity. High Cronbach's α (0.94) and intraclass correlation coefficients (0.89-0.95) supported reliability. A high correlation between the 7-day average ASD score and the Asthma Control Questionnaire (ACQ) total score (r = 0.75) and Asthma Quality of Life Questionnaire total scores (r = -0.76), and a moderate correlation with FEV1% predicted (r = -0.30) supported convergent validity. Significant differences (P < .001) between groups classified by ACQ scores supported known-group validity. The 7-day average ASD scores were responsive to change, with significantly higher score changes (P < .001) in responders versus nonresponders. Minimally important differences were calculated and found to be in the range of 0.1-0.3.
CONCLUSION: Results of this study indicated that the ASD is a reliable and valid asthma symptom measure for use in adult and adolescent asthma patients to evaluate the effect of treatment on asthma in clinical trials.
Copyright © 2015 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Asthma; Patient-reported outcome; Psychometrics; Symptoms; Validity

Mesh:

Year:  2015        PMID: 26549745     DOI: 10.1016/j.jaip.2015.07.008

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


  6 in total

1.  Mixed-methods content and sentiment analysis of adolescents' voice diaries describing daily experiences with asthma and self-management decision-making.

Authors:  Jennifer R Mammen; James J Java; Hyekyun Rhee; Arlene M Butz; Jill S Halterman; Kimberly Arcoleo
Journal:  Clin Exp Allergy       Date:  2018-09-18       Impact factor: 5.018

2.  Effectiveness and safety of a microcrystalline tyrosine-adjuvanted Dermatophagoides pteronyssinus allergoid immunotherapy in adult patients with allergic asthma and rhinitis: A real-life prospective observational study.

Authors:  Clara Padró; Diego Gutiérrez; Francisco Moreno; Antonio Parra; Manuel J Rial; Ramón Lleonart; Carla Torán-Barona; José L Justicia; Albert Roger
Journal:  Immun Inflamm Dis       Date:  2022-05

3.  Development and psychometric validation of the Nausea/Vomiting Symptom Assessment patient-reported outcome (PRO) instrument for adults with secondary hyperparathyroidism.

Authors:  Colleen A McHorney; Mark E Bensink; Laurie B Burke; Vasily Belozeroff; Chad Gwaltney
Journal:  J Patient Rep Outcomes       Date:  2018-02-13

4.  Is the EQ-5D fit for purpose in asthma? Acceptability and content validity from the patient perspective.

Authors:  Diane Whalley; Gary Globe; Rebecca Crawford; Lynda Doward; Eskinder Tafesse; John Brazier; David Price
Journal:  Health Qual Life Outcomes       Date:  2018-08-03       Impact factor: 3.186

5.  The construct validity and responsiveness of the EQ-5D-5L, AQL-5D and a bespoke TTO in acute asthmatics.

Authors:  Christina-Jane Crossman-Barnes; Tracey Sach; Andrew Wilson; Garry Barton
Journal:  Qual Life Res       Date:  2019-11-02       Impact factor: 4.147

6.  NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma.

Authors:  Andrew Menzies-Gow; Gene Colice; Janet M Griffiths; Gun Almqvist; Sandhia Ponnarambil; Primal Kaur; Gennaro Ruberto; Karin Bowen; Åsa Hellqvist; May Mo; Esther Garcia Gil
Journal:  Respir Res       Date:  2020-10-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.